CA2836827C - Alpha amino acid ester-drug conjugates hydrolysable by carboxylesterases - Google Patents

Alpha amino acid ester-drug conjugates hydrolysable by carboxylesterases Download PDF

Info

Publication number
CA2836827C
CA2836827C CA2836827A CA2836827A CA2836827C CA 2836827 C CA2836827 C CA 2836827C CA 2836827 A CA2836827 A CA 2836827A CA 2836827 A CA2836827 A CA 2836827A CA 2836827 C CA2836827 C CA 2836827C
Authority
CA
Canada
Prior art keywords
amino acid
inhibitor
ester
conjugate
acid ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2836827A
Other languages
English (en)
French (fr)
Other versions
CA2836827A1 (en
Inventor
Alan Hornsby Davidson
Alan Hastings Drummond
Lindsey Ann Needham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrophage Pharma Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Priority claimed from CA2607020A external-priority patent/CA2607020C/en
Publication of CA2836827A1 publication Critical patent/CA2836827A1/en
Application granted granted Critical
Publication of CA2836827C publication Critical patent/CA2836827C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA2836827A 2005-05-05 2006-05-04 Alpha amino acid ester-drug conjugates hydrolysable by carboxylesterases Active CA2836827C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0509226.7 2005-05-05
GB0509226A GB0509226D0 (en) 2005-05-05 2005-05-05 Enzyme and receptor modulation
US68054205P 2005-05-13 2005-05-13
US60/680,542 2005-05-13
CA2607020A CA2607020C (en) 2005-05-05 2006-05-04 Alpha amino acid ester-drug conjugates hydrolysable by carboxylesterases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2607020A Division CA2607020C (en) 2005-05-05 2006-05-04 Alpha amino acid ester-drug conjugates hydrolysable by carboxylesterases

Publications (2)

Publication Number Publication Date
CA2836827A1 CA2836827A1 (en) 2006-11-09
CA2836827C true CA2836827C (en) 2016-05-03

Family

ID=34685158

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2836827A Active CA2836827C (en) 2005-05-05 2006-05-04 Alpha amino acid ester-drug conjugates hydrolysable by carboxylesterases

Country Status (10)

Country Link
CN (1) CN101171039B (zh)
CA (1) CA2836827C (zh)
DK (1) DK1877098T3 (zh)
ES (2) ES2415244T3 (zh)
GB (1) GB0509226D0 (zh)
NZ (1) NZ561710A (zh)
PT (1) PT1877098E (zh)
SG (1) SG2014007512A (zh)
SI (1) SI1877098T1 (zh)
ZA (1) ZA200708283B (zh)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200601252A1 (ru) * 1999-09-08 2006-10-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
JP2007509082A (ja) * 2003-10-22 2007-04-12 アルピダ エー/エス ペプチドデホルミラーゼ阻害剤としてのベンゾイミダゾール誘導体類およびそれらの使用

Also Published As

Publication number Publication date
SG2014007512A (en) 2014-03-28
GB0509226D0 (en) 2005-06-15
CN101171039B (zh) 2013-01-23
DK1877098T3 (da) 2013-07-08
PT1877098E (pt) 2013-07-31
ES2415244T3 (es) 2013-07-24
CN101171039A (zh) 2008-04-30
ZA200708283B (en) 2008-10-29
CA2836827A1 (en) 2006-11-09
NZ561710A (en) 2010-08-27
ES2577433T3 (es) 2016-07-14
SI1877098T1 (sl) 2013-08-30

Similar Documents

Publication Publication Date Title
CA2607020C (en) Alpha amino acid ester-drug conjugates hydrolysable by carboxylesterases
US9636409B2 (en) Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters
ES2509342T3 (es) Hidroxamatos como inhibidores de histona desacetilasa
Tenora et al. Tumor-targeted delivery of 6-diazo-5-oxo-l-norleucine (DON) using substituted acetylated lysine prodrugs
EP2949344A2 (en) Use of intracellular enzymes for the release of covalently linked bioactives
ES2909086T3 (es) Inhibidores bicíclicos de histona desacetilasa
McDonnell et al. Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling
Sodji et al. Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids
Suzuki et al. Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors
Belvedere et al. Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors
US8921595B2 (en) Protein Arginine Deiminase inhibitors as novel therapeutics for rheumatoid arthritis and cancer
Routholla et al. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model
CA2836827C (en) Alpha amino acid ester-drug conjugates hydrolysable by carboxylesterases
Hu et al. The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseases
US11203596B2 (en) Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131217